Johnson & Johnson (JNJ) recently released its earnings results for the fourth quarter, and while the company reported slight upside in both earnings per shareEarnings per share (EPS) is a fundamental financial metric that provides valuable insights into a company's profitability. This widely used indicator helps investors and analysts g... More (EPS) and revenue, investors seemed underwhelmed by the performance. In this article, we delve into the details of JNJ’s Q4 earnings report, examining its financial results, segment performance, and the outlook for 2024.
Modest Upside in Q4 Earnings
Johnson & Johnson reported earnings results for the fourth quarter of 2023 that included a slight upside. While the company’s earnings per share exceeded expectations, it was the smallest upside in eight quarters. This suggests that JNJ faced some challenges in the quarter, impacting its ability to deliver a substantial earnings beat.
Similarly, JNJ’s revenue for the quarter exhibited a modest upside. The company has a history of reporting revenue figures that tend to be relatively conservative, and this quarter was no exception. While JNJ’s revenue outperformed expectations, it was a bit more modest than what is typically observed. Despite these dynamics, the company reaffirmed its prior guidance for 2024.
Segment Performance
To understand JNJ’s Q4 performance better, let’s examine its two major segments: Innovative Medicine and MedTech.
Innovative Medicine (IM) Segment
In Q4, the Innovative Medicine segment of Johnson & Johnson saw operational sales grow by 4.2% year-over-year, reaching $13.72 billion. Notably, this segment experienced robust growth of 9.5% in the United States, but outside of the U.S., it faced a decline of 3.1%. The international decline was primarily attributed to the loss of exclusivity for the drug ZYTIGA in Europe.
The growth in the IM segment was driven by key brands and continued uptake of recently launched products. Nine assets within this segment delivered double-digit growth, contributing to its overall performance.
MedTech Segment
Johnson & Johnson’s MedTech segment showed more substantial growth in Q4, with sales rising by 13.3% year-over-year to $7.67 billion. A part of this strong growth can be attributed to JNJ’s recent acquisition of Abiomed. Both the U.S. and international markets witnessed impressive growth, with rates of 14.1% and 12.8%, respectively.
Electrophysiology was a standout within the MedTech segment, experiencing robust growth of 25.2% across all regions, including Europe. The company attributed this growth to its global market-leading portfolio, including recently launched catheters.
Outlook for 2024
Johnson & Johnson provided its outlook for 2024, forecasting operational sales growth of 5-6%, translating to a range of $88.2 to $89.0 billion. It’s important to note that this guidance excludes any impact from COVID-19 vaccine sales.
In the IM segment, JNJ anticipates delivering a 13th consecutive year of above-market growth. This growth is expected to be driven by market share gains from key brands like DARZALEX and continued adoption of recently launched products.
Within the MedTech segment, the company plans to further shift its portfolio into high-growth markets while expanding its reach and scale globally. Notably, JNJ expects procedures in 2024 to remain above pre-COVID levels, indicating that its MedTech segment is benefiting from the backlog of surgical procedures that were postponed during the pandemic.
Bottom-line: While Johnson & Johnson’s Q4 earnings report did deliver modest upside in EPS and revenue, it appears to have left investors somewhat underwhelmed. The small earnings beat was unusual for JNJ, and it may have disappointed those with higher expectations. Additionally, some investors might have hoped for a more optimistic guidance range for 2024, but the company maintained its prior outlook.
Another factor contributing to market sentiment could be the stock’s upward trajectory since its Q3 report in late October. Elevated expectations might have influenced the market’s reaction to the Q4 results.
In conclusion, Johnson & Johnson’s Q4 report for 2023 showed a mix of positive and slightly disappointing aspects. The company’s ability to navigate challenges and capitalize on growth opportunities in 2024 will be closely monitored by investors as they assess its performance in the evolving healthcare landscape.
💥 GET OUR LATEST CONTENT IN YOUR RSS FEED READER
We are entirely supported by readers like you. Thank you.🧡
This content is provided for informational purposes only and does not constitute financial, investment, tax or legal advice or a recommendation to buy any security or other financial asset. The content is general in nature and does not reflect any individual’s unique personal circumstances. The above content might not be suitable for your particular circumstances. Before making any financial decisions, you should strongly consider seeking advice from your own financial or investment advisor.
